Chris Heberlig Net Worth

Chris Heberlig biography

Chris Heberlig serves as President, Chief Financial Officer of the Company. Mr. Heberlig is a seasoned executive with significant experience in managing and leading teams as well as overseeing the financial and operational responsibilities of private and publicly traded bio-technology companies. He has over twenty years of experience and currently serves as a financial consultant focused on the life sciences industry, most recently serving at Danforth Advisors LLC since September 2020 and at 2C Advisory LLC since June 2020. His experience includes senior management roles, including previously serving as Executive Vice President and Chief Financial Officer of publicly held Kiniksa Pharmaceuticals Ltd. from August 2015 to March 2020 and as a consultant for the company until June 2020. Mr. Heberlig previously served as Senior Vice President, Finance and Business Operations and Chief Accounting Officer of publicly held, Synageva Biopharma Corp. Earlier in his career, he held senior financial management positions at Panacos Pharmaceuticals Inc. and EPIX Pharmaceuticals Inc., both publicly traded biotechnology companies. Mr. Heberlig began his career at PwC, a national audit, tax, and advisory services firm. He received his MBA degree from Boston University and a BA in economics from St. Lawrence University. He is also a Certified Public Accountant.

How old is Chris Heberlig?

Chris Heberlig is 45, he's been the President and Chief Financial Officer of Organovo Inc since 2020. There are 3 older and no younger executives at Organovo Inc. The oldest executive at Organovo Holdings Inc is Adam Stern, 56, who is the Independent Director.

What's Chris Heberlig's mailing address?

Chris's mailing address filed with the SEC is 440 STEVENS AVENUE, SUITE 200, , SOLANA BEACH, CA, 92075.

Insiders trading at Organovo Inc

Over the last 13 years, insiders at Organovo Inc have traded over $8,085,375 worth of Organovo Inc stock and bought 386,250 units worth $661,443 . The most active insiders traders include Mark Kessel, Keith Murphy, and Adam K Stern. On average, Organovo Inc executives and independent directors trade stock every 112 days with the average trade being worth of $29,354. The most recent stock trade was executed by David Gobel on 15 November 2023, trading 19,607 units of ONVO stock currently worth $31,763.

What does Organovo Inc do?

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.

Organovo Inc executives and stock owners

Organovo Inc executives and other stock owners filed with the SEC include:

• Steven Hughes,
  Chief Medical Officer
• Keith Murphy,
  Executive Chairman and Principal Executive Officer
• Steve Kunszabo,
  VP, Investor Relations & Corporate Communications
• Adam Stern,
  Independent Director
• Alison Milhous,
  Independent Director
• David Gobel,
  Independent Director
• Douglas Cohen,
  Independent Director
• Thomas Jurgensen,
  General Counsel
• Jeffrey Miner,
  Chief Scientific Officer
• Chris Heberlig,
  President, Chief Financial Officer
• David Shapiro,
  Director
• Craig Kussman,
  Chief Financial Officer
• Robert Jr. Baltera,
  Director
• Paul Gallant,
  General Manager
• Jennifer Bush,
  General Counsel & Secretary
• Kirk Malloy,
  Director
• Mark Kessel,
  Director
• Taylor Crouch,
  CEO & President
• James T Glover,
  Director
• Sharon Collins Presnell,
  Chief Scientific Officer
• Richard E Maroun,
  Director
• Tamar D Howson,
  Director
• Kevin Kimberlin,
  10% owner
• Richard A. Heyman,
  Director
• Michael Renard,
  EVP of Commercial Operations
• Andras Forgacs,
  Director
• Barry D Michaels,
  Chief Financial Officer
• Eric David,
  CSO & EVP Pre-Clinical Dev
• Carolyn Beaver,
  Director
• Vaidehi Joshi,